Bristol Myers Squibb (CELG-RI) Minority Interest (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Minority Interest of $34.0 million for Q1 2026, down 42.37% year-over-year from $59.0 million in Q1 2025, and up 3.03% quarter-over-quarter from $33.0 million in Q4 2025.
Bristol Myers Squibb (CELG-RI) Minority Interest (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Minority Interest data on file, last reported at $34.0 million in Q1 2026.
- Minority Interest for Q1 2026 came in at $34.0 million, down 42.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.0 million (down 42.37% YoY), and the FY2025 annual result was $33.0 million, down 37.74% from the prior year.
- Minority Interest climbed to $34.0 million in Q1 2026 per CELG-RI's latest filing, from $33.0 million in the prior quarter.
- Over five years, Minority Interest peaked at $65.0 million in Q1 2022 and troughed at $33.0 million in Q4 2025.
- A 5-year average of $55.0 million and a median of $57.0 million in 2022 frame the typical range for Minority Interest.
- The sharpest annual moves came in 2025 and 2026: Minority Interest climbed 1.72% in 2025, then plunged 42.37% in 2026.
- A 5-year view of Minority Interest shows it stood at $57.0 million in 2022, then fell by 3.51% to $55.0 million in 2023, then dropped by 3.64% to $53.0 million in 2024, then plunged by 37.74% to $33.0 million in 2025, then rose by 3.03% to $34.0 million in 2026.
- Business Quant data shows CELG-RI's Minority Interest at $34.0 million in Q1 2026, $33.0 million in Q4 2025, and $48.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.00 Mn |
| Dec 31, 2025 | 33.00 Mn |
| Sep 30, 2025 | 48.00 Mn |
| Jun 30, 2025 | 54.00 Mn |
| Mar 31, 2025 | 59.00 Mn |
| Dec 31, 2024 | 53.00 Mn |
| Sep 30, 2024 | 58.00 Mn |
| Jun 30, 2024 | 54.00 Mn |
| Mar 31, 2024 | 58.00 Mn |
| Dec 31, 2023 | 55.00 Mn |
| Sep 30, 2023 | 64.00 Mn |
| Jun 30, 2023 | 57.00 Mn |
| Mar 31, 2023 | 62.00 Mn |
| Dec 31, 2022 | 57.00 Mn |
| Sep 30, 2022 | 63.00 Mn |
| Jun 30, 2022 | 61.00 Mn |
| Mar 31, 2022 | 65.00 Mn |
| Dec 31, 2021 | 60.00 Mn |
| Sep 30, 2021 | 71.00 Mn |
| Jun 30, 2021 | 66.00 Mn |